Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

1698 - Pharmacokinetic (PK) analysis of concurrent administration of enzalutamide (enza) and crizotinib (crizo) in patients with metastatic castration resistant prostate cancer (CRPC)

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Clinical Research

Tumour Site

Prostate Cancer

Presenters

abhishek tripathi

Citation

Annals of Oncology (2018) 29 (suppl_8): viii271-viii302. 10.1093/annonc/mdy284

Authors

A. tripathi1, J.G. Supko2, K.P. Gray3, Z. Melnick1, M. Taplin1, A.D. Choudhury1, M. Pomerantz1, J. Bellmunt1, C. Yu1, Z. Sun4, S. Srinivas5, P.W. Kantoff6, C. Sweeney7, L.C. Harshman1

Author affiliations

  • 1 Lank Center For Genitourinary Oncology, Dana-Farber Cancer Institute, 02215 - Boston/US
  • 2 Clinical Pharmacology Laboratory, Massachusetts general Hospital, Boston/US
  • 3 Biostatistics And Computational Biology, Dana-Farber Cancer Institute, Boston/US
  • 4 Department Of Urology, Stanford University, 94305 - Stanford/US
  • 5 Department: Medicine - Med/oncology, Stanford University, 94305 - Stanford/US
  • 6 Department Of Medical Oncology, Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 7 Medical Oncology, Dana-Farber Cancer Institute, 02215 - Boston/US
More

Resources

Abstract 1698

Background

Androgen receptor (AR) inhibition can upregulate c-MET expression which can drive CRPC progression. We have previously described the safety and toxicity profile of concurrent treatment with enza and crizo, a potent c-MET inhibitor in a phase 1 study. Since crizo is a substrate for CYP3A4, which is strongly induced by enza, we performed a PK analysis to evaluate its impact on steady state crizo levels.

Methods

A 3 + 3 dose escalation design was employed to test increasing doses of crizo at 250mg daily (dose level 1; n = 3), 200 mg BID (dose level 2; n = 6) and 250mg BID (dose level 3; n = 15) in combination with a fixed dose of enza 160 mg daily in 28 day cycles. PK samples drawn during cycle 2 were used to estimate steady state PK parameters including peak (Cmaxss) and trough (Cminss) plasma concentration and area under the curve over a dosing interval (AUCτss), reported as the geometric mean ± SD.

Results

The crizo Cminss increased progressively across dose levels from 20.7 ± 1.8 ng/mL (250 mg QD) to 70.2 ± 36.4 ng/mL (250 mg BID). Among the 12 patients enrolled on dose level 3 with available PK data, the crizo Cmaxss and AUCτss were 104 ± 45 ng/mL and 1,000 ± 476 ng-h/mL respectively. This represents a 73.8% decrease in crizo steady state exposure compared to a historical data for NSCLC patients with normal renal function treated with crizo monotherapy at 250 mg BID (Cminss: 285.0 ng/mL; Cmaxss: 315 ng/mL and AUCτss: 3,817 ng-h/mL; Tan et al Inv. New Drugs 2016). Enza Cminss was similar across the crizo dose levels (250mg QD: 10.6 ± 4.6 μg/mL; 250mg BID: 12.5 ± 3.2 μg/mL) and was in excellent agreement with previously reported steady state levels in the phase 3 AFFIRM trial (11.7 ± 2.9μg/mL; Gibbons et al Clin Pharmacokinetics 2015).

Conclusions

Concurrent administration of enza resulted in a clinically significant ∼74% increase in the apparent oral clearance of crizo suggestive of a clinically significant PK drug interaction. Further investigation into the optimal combination of c-MET inhibitors with novel AR inhibitors is required. Our results highlight the importance of considering PK interactions when evaluating novel combination strategies in CRPC.

Clinical trial identification

NCT02207504.

Legal entity responsible for the study

Dana-Farber Cancer Institute.

Funding

Astellas Pharma Inc.

Editorial Acknowledgement

n/a

Disclosure

K.P. Gray: Stock ownership: DVAX M-E. Taplin: Research funding, Advisory board, Honorarium: Medivation/Pfizer. A.D. Choudhury: Honoraria: Bayer, Astellas Australia, Janssen Latin America; Research funding: Bayer (pending). M. Pomerantz: Advisory Board/committee: NCI/PDQ; Speakers bureau: Astellas, APACE, MD Anderson, PCF. J. Bellmunt: Advisory role: Genentech, MSD, Pfizer, GSK, BMS, Pierre-Fabre, Sanofi Aventis, Astellas, OncoGenex, Janssen; Lectures fee: Pfizer, MSD, GSK, Novartis, Pierre-Fabre, Astellas; Research funding: Takeda, Pfizer, Novartis, Sanofi Aventis. C. Yu: Employee: Daiichi Sankyo, Inc. S. Srinivas: Advisory board; Research funding: Exelexis DSMC: Pfizer P.W. Kantoff: Scientific Advisory board; BIND Biosciences, Inc., BN Immunotherapeutics. Context Therapeutics LLC, DRGT, GE Healthcare, Janssen, Metamark (-no longer in business), New England Research Institutes, Inc., OncoCellMDX, Progenity, Sanofi, Seer Biosciences, Tarveda Therapeutics (previously Blend), Thermo Fisher; Investment interests: Context Therapeutics, DRGT, placon, Seer, Tarveda therapeutics. C. Sweeney: Stock or Other ownership: Leuchemix Consulting; Advisory Role: Sanofi, Janssen Biotech, Astellas Pharma, Bayer, Genentech, AstraZeneca, Pfizer, Tolmar; Research funding: Janssen Biotech (Inst), Astellas Pharma (Inst), Sanofi (Inst), Bayer (Inst), Sotio (Inst) Patents, royalties; Other Intellectual Property: Leuchemix: Parthenolide, dimethylaminoparthenolide; Exelixis: Abiraterone plus cabozantinib combination L.C. Harshman: Advisory role: Bayer, Genentech, Dendreon, Pfizer, Medivation/Astellas, Kew Group, Theragene, Corvus, Merck, Exelixis, Novartis; Research institution: Bayer, Sotio, Bristol-Myers Squib, Merck, Takeda, Dendreon/Valient, Jannsen, Medivation/Astellas, Genentech, Pfizer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.